Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PHAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Controlled Company (new) — Only Class B shareholders can appoint directors until a business combination, giving the sponsor control and allowing Nasdaq controlled-company exemptions.
Phalanx Acquisition Corp I files for $175M SPAC IPO at $10 per unit, targeting fintech deals
Filed July 16, 2026 · ~1 min read
Key Changes
-
high
Offering 17.5M units at $10.00 each for $175M gross proceeds; net proceeds to company are $1.2M, with $175M placed in trust.
The Offering verify on EDGAR → -
high
Sponsor will own 20% post-offering via 4.375M founder shares bought for $25,000; public shareholders face immediate dilution.
The Offering verify on EDGAR → -
high
Only Class B holders vote on director appointments until a business combination, making it a Nasdaq 'controlled company'.
-
high
Auditor's report includes a going-concern explanatory paragraph, indicating substantial doubt about the company's ability to continue.
Experts view on EDGAR → -
medium
No target identified; company will focus on financial services/fintech businesses valued $1.0–up to $3.0B.
Business view on EDGAR →
Summary
Phalanx Acquisition Corp I, a blank-check company, is seeking to raise $175 million in an IPO by offering 17.5 million units at $10.00 each. The company will place $175 million into a trust account, while retaining approximately $1.2 million in net proceeds for operating expenses.
The sponsor, Celeres Capital, will own 20% of the company after the offering through founder shares acquired for a nominal $25,000, creating immediate dilution for public investors. The company has not yet identified a business combination target but plans to focus on financial services and fintech companies valued between $1.0 billion and $3.0 billion. Investors should be aware of significant governance risks.
Only holders of Class B ordinary shares—the sponsor and insiders—can vote on director appointments until a business combination is completed, which means public shareholders have no say in board composition during the search phase. This structure qualifies the company as a 'controlled company' under Nasdaq rules, potentially exempting it from certain corporate governance requirements. Additionally, the auditor's report includes a going-concern explanatory paragraph, signaling substantial doubt about the company's ability to continue as a going concern if it fails to complete a business combination. These red flags, combined with the sponsor's low-cost founder shares and anti-dilution protections, mean public investors bear significant risk. The company's ability to complete a deal is uncertain, and if it fails, shareholders may receive only about $10.00 per share from the trust account, less than the offering price after expenses. Prospective investors should carefully review the full prospectus, including the dilution table and risk factors, before participating.
Section-by-Section Diff
The Offering · The Offering
SPAC offering 17.5M units at $10 each, with founder shares at 20% post-offering and warrants exercisable at $11.50.
Added in current filing · verify on EDGAR →
17,500,000 units, at $10.00 per unit
The company is offering 17.5 million units at $10.00 per unit, each consisting of one Class A ordinary share and one-half of one redeemable warrant. This is the primary offering size and price.
Added in current filing · verify on EDGAR →
4,375,000 Class B ordinary shares (or founder shares)
After the offering, there will be 4,375,000 founder shares outstanding, representing 20% of the total 21,875,000 shares. The founder shares were acquired for approximately $0.004 per share, a nominal cost compared to the $10.00 public offering price.
Added in current filing · verify on EDGAR →
$175,000,000, or $201,250,000 if the underwriters’ over-allotment option is exercised in full ($10.00 per unit in either case), will be placed in a U.S. based trust account
The company will place $175 million (or $201.25 million if the over-allotment is exercised) into a trust account, representing $10.00 per unit. This amount includes $7 million in deferred underwriting commissions.
Added in current filing · verify on EDGAR →
Prior to the consummation of our initial business combination, only holders of our Class B ordinary shares will (i) have the right to vote on the appointment and removal of directors
Before the business combination, only Class B shareholders (founders) can vote on director appointments and removals. Class A shareholders have no vote on these matters during this period, concentrating control with the sponsor.
Added in current filing · verify on EDGAR →
The amount in the trust account is initially anticipated to be $10.00 per public share.
The trust account is expected to hold $10.00 per public share, which is the per-share redemption price. The section does not state the total number of units or the aggregate offering amount, but it references 17,500,000 public shares sold in this offering.
Added in current filing · verify on EDGAR →
We will provide our public shareholders with the opportunity to redeem, regardless of whether they abstain, vote for, or vote against, our initial business combination, all or a portion of their public shares upon the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (less taxes payable), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein.
Public shareholders can redeem their shares for a pro rata portion of the trust account upon a business combination, regardless of how they vote. This is a key investor protection in SPACs.
Added in current filing · verify on EDGAR →
Upon the closing of this offering, assuming the underwriters’ over-allotment is not exercised, our sponsor will have invested in us an aggregate of $3,775,000, comprised of the $25,000 purchase price for the founder shares (or approximately $0.005 per share) and the $3,750,000 purchase price for the private placement warrants (or $1.00 per warrant).
The sponsor paid only $25,000 for founder shares (about $0.004 per share) and $3,750,000 for private placement warrants, giving insiders a very low cost basis relative to public investors. This creates a conflict of interest because insiders may be incentivized to complete a business combination even if it is not in the best interest of public shareholders.
Added in current filing · verify on EDGAR →
Our sponsor will control the appointment of our board of directors until consummation of our initial business combination and will hold a substantial interest in us. As a result, it will appoint all of our directors prior to the consummation of our initial business combination and may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner that you do not support.
The sponsor controls board appointments and holds a substantial interest, which may lead to decisions that public shareholders do not support. This is a governance risk specific to this blank check company.
Use of Proceeds · Use of Proceeds
SPAC offering 17.5M units at $10.00; $175M (100% of public offering) goes to trust, $1.25M retained for expenses.
Added in current filing · verify on EDGAR →
We are offering 17,500,000 units at an offering price of $10.00 per unit.
The company is offering 17.5 million units at $10.00 each, for gross proceeds of $175 million from the public offering. This is a preliminary offering size and price as stated in the S-1.
Added in current filing · verify on EDGAR →
$175,000,000 ($10.00 per unit), or $201,250,000 if the underwriters’ over-allotment option is exercised in full ($10.00 per unit), will be placed in a U.S. based trust account
100% of the public offering proceeds will be held in a trust account, which is typical for SPACs. The trust account is intended to fund redemptions or the business combination.
Added in current filing · verify on EDGAR →
The following table shows the use of the approximately $1,250,000 of net proceeds not held in the trust account
Only $1.25 million of the net proceeds will be available for operating expenses before the business combination. The table details allocations including $360,000 for advisory services to the sponsor's managing member and $240,000 for office space and administrative support.
Added in current filing · verify on EDGAR →
The underwriters have agreed to defer underwriting commissions equal to $0.40 per unit on units other than those sold pursuant to the underwriters’ over-allotment option and $0.60 per unit on units sold pursuant to the underwriters’ over-allotment option, or $7,000,000 in the aggregate or up to $8,575,000 in the aggregate if the underwriters’ over-allotment option is exercised in full.
A significant portion of underwriting commissions is deferred and will be paid from the trust account upon completion of the business combination. This reduces the amount available to the post-combination company.
Added in current filing · verify on EDGAR →
the FPA Provider, an affiliate of our sponsor, has agreed, pursuant to a forward purchase agreement with us, to purchase, in a private placement to occur concurrently with the consummation of our initial business combination, up to $25,000,000 of our securities.
An affiliate of the sponsor has committed to purchase up to $25 million of securities at the time of the business combination, subject to conditions. This could provide additional funding but is not guaranteed.
Dilution · Dilution
SPAC dilution table shows NTBV per share from $7.71 to -$1.47 depending on redemptions and over-allotment.
Added in current filing · verify on EDGAR →
our public shareholders may experience material dilution from the exercise of the 5,500,000 private placement warrants (whether or not the underwriters’ over-allotment option is exercised) to be purchased by our sponsor, Cantor Fitzgerald & Co and Odeon Capital Group LLC.
The prospectus warns that public shareholders could face significant dilution from 5.5 million private placement warrants purchased by the sponsor and underwriters. These warrants are exercisable after the business combination and are not reflected in the dilution table.
Added in current filing · verify on EDGAR →
up to $1,500,000 of such loans may be convertible into warrants of the post-business combination entity at a price of $1.00 per warrant at the option of our sponsor, which conversion and warrant exercise may result in material dilution to our public shareholders.
The sponsor can convert up to $1.5 million of working capital loans into warrants at $1.00 each, potentially adding further dilution. This is in addition to the private placement warrants and is not included in the dilution table.
Added in current filing · verify on EDGAR →
the issuance of additional ordinary or preference shares may significantly dilute the equity interest of public shareholders, which dilution would even further increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares.
Class B ordinary shares have anti-dilution provisions that could cause them to convert into more than one Class A share each, increasing dilution for public shareholders. This is a company-specific risk beyond standard SPAC dilution.
Added in current filing · verify on EDGAR →
Assuming Full Exercise of Over-Allotment Option 7.71 | 7.13 | 2.87 | 6.18 | 3.82 | 4.26 | 5.74 | (1.47) | 11.47
The table shows NTBV per share ranging from $7.71 with no redemptions to -$1.47 with maximum redemptions, assuming full over-allotment. The difference between NTBV and the $10.00 offering price ranges from $2.87 to $11.47, indicating substantial dilution in high-redemption scenarios.
Risk Factors · Risk Factors
SPAC risk factors: public shareholders may not get a vote, founder shares dilute, and redemption rights can reduce cash for a deal.
Added in current filing · verify on EDGAR →
Our initial shareholders will own 20% of our issued and outstanding ordinary shares immediately following the completion of this offering (assuming our initial shareholders do not purchase any units in this offering).
The filing states that initial shareholders will own 20% of ordinary shares after the offering. This is a standard SPAC founder stake, but it means public investors start with diluted ownership. The risk section also notes that founder shares vote on the business combination, so a deal can pass even if most public shareholders oppose it.
Added in current filing · verify on EDGAR →
if we would require an ordinary resolution, we would need 6,562,501 public shares, or 37.5% of the 17,500,000 public shares sold in this offering, and if we would require a special resolution, we would need 10,281,251 public shares, or 58.8% of the 17,500,000 public shares sold in this offering, to be voted in favor of an initial business combination in order to have our initial business combination approved
The filing gives specific vote thresholds: with all shares voted, an ordinary resolution needs 37.5% of public shares and a special resolution needs 58.8%. Because founder shares vote in favor, the public support needed is lower than a simple majority of all shares. This is a key governance risk for public shareholders.
Added in current filing · verify on EDGAR →
If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination.
The company acknowledges a material risk that it could be classified as an investment company under the Investment Company Act, which would impose significant regulatory burdens and could prevent completion of its business combination. This is a SPAC-specific risk tied to the nature of its trust account investments and the SEC's recent SPAC rules.
Added in current filing · verify on EDGAR →
We may issue additional Class A ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. We may also issue Class A ordinary shares upon the conversion of the founder shares at a ratio greater than one-to-one at the time of our initial business combination as a result of the anti-dilution provisions contained therein. Any such issuances would dilute the interest of our shareholders and likely present other risks.
The company explicitly warns that it may issue substantial additional shares, including through PIPE transactions and anti-dilution adjustments on founder shares, which would dilute public shareholders. This is a key economic risk for investors in a SPAC IPO.
Added in current filing · verify on EDGAR →
Unlike some other similarly structured special purpose acquisition companies, our initial shareholders will receive additional Class A ordinary shares if we issue certain shares to consummate an initial business combination as anti-dilution protection to the initial shareholders.
The company highlights that its initial shareholders (sponsor) have anti-dilution protection that will increase their ownership percentage if additional shares are issued for the business combination. This is a structural feature that benefits insiders at the expense of public shareholders.
Added in current filing · verify on EDGAR →
The FPA Provider has agreed, pursuant to a Forward Purchase Agreement with us, to purchase, in a private placement to occur concurrently with the consummation of our initial business combination, up to $25,000,000 of our securities.
The company may rely on up to $25 million from the Forward Purchase Agreement to fund its initial business combination. If the FPA Provider fails to fund, the company may lack sufficient funds to complete a deal or may need alternative financing.
Added in current filing · verify on EDGAR →
Since only holders of our Class B ordinary shares will have the right to vote on the appointment of directors, upon the listing of our shares on Nasdaq, Nasdaq will consider us to be a “controlled company” within the meaning of Nasdaq rules and, as a result, we may qualify for exemptions from certain corporate governance requirements.
Public shareholders have no vote on director appointments before the business combination. The company may use the controlled company exemption to avoid independent director and compensation committee requirements, reducing shareholder protections.
Added in current filing · verify on EDGAR →
Upon closing of this offering, our sponsor will own 20% of our issued and outstanding ordinary shares (assuming it does not purchase any units in this offering).
The sponsor will hold 20% of ordinary shares and, through Class B voting rights, controls director appointments until the business combination. This concentration of influence may disadvantage public shareholders.
MD&A · Management's Discussion and Analysis
Blank check company with no operations or revenue, planning a $175M trust account from a $176.25M net offering to fund a future business combination.
Added in current filing · verify on EDGAR →
We estimate that the net proceeds from the sale of the units in this offering and the sale of the private placement warrants for an aggregate purchase price of $5,500,000 (whether or not the underwriters’ over-allotment option is exercised), after deducting offering expenses of approximately $750,000 and underwriting commissions of $3,500,000 (excluding deferred underwriting commissions of $7,000,000, or $8,575,000 if the underwriters’ over-allotment option is exercised in full), will be $176,250,000 (or $202,500,000 if the underwriters’ over-allotment option is exercised in full). $175,000,000 (or $201,250,000 if the underwriters’ over-allotment option is exercised in full) will be held in the trust account, which includes the deferred underwriting commissions described above.
The company estimates net proceeds of $176.25 million (or $202.5 million with over-allotment) from the offering and private placement warrants. Of that, $175 million (or $201.25 million) goes into the trust account, which includes deferred underwriting commissions. The remaining approximately $1.25 million is held outside the trust for operating expenses.
Added in current filing · verify on EDGAR →
Additionally, the FPA Provider, an affiliate of our sponsor, has agreed, pursuant to a forward purchase agreement with us, to purchase, in a private placement to occur concurrently with the consummation of our initial business combination, up to $25,000,000 of our securities.
An affiliate of the sponsor has committed to purchase up to $25 million of securities in a private placement at the time of the business combination. This provides potential additional funding but is subject to conditions including board approval and the FPA Provider's investment committee approval. The company has not obligated the FPA Provider to reserve funds, so the proceeds may not be received.
Added in current filing · verify on EDGAR →
Our liquidity needs have been satisfied prior to the completion of this offering through $25,000 paid by the sponsor to cover certain of our offering and formation costs in exchange for the issuance of the founder shares to our sponsor and $500,000 in loans from our sponsor.
The company has been funded by the sponsor through a $25,000 payment for founder shares and $500,000 in loans. These loans may be repaid or converted into private placement warrants at $1.00 per warrant, up to $1.5 million. The terms of such loans have not been determined and no written agreements exist.
Added in current filing · verify on EDGAR →
We expect our primary liquidity requirements during that period to include approximately $150,000 for legal, accounting, due diligence, travel, and other expenses associated with structuring, negotiating and documenting successful business combinations; $150,000 for legal and accounting fees related to regulatory reporting requirements; $81,000 for Nasdaq and other regulatory fees; $240,000 for office space and administrative services and consulting fees; $360,000 for advisory services relating to our search for and consummation of an initial business combination; approximately $225,000 for directors’ and officers’ liability insurance; and approximately $44,000 for general working capital that will be used for miscellaneous expenses and reserves.
The company provides a detailed breakdown of expected expenses before a business combination, totaling approximately $1.25 million. These are estimates and may differ materially from actual expenses. The funds come from the portion of offering proceeds held outside the trust account.
Added in current filing · verify on EDGAR →
We have neither engaged in any operations nor generated any revenues to date.
The company is a blank check company with no operating history or revenue. It will not generate operating revenues until after completing a business combination. This is typical for SPACs but highlights the speculative nature of the investment.
Business · Business
Blank-check company targeting financial services/fintech businesses valued $1.0–up to $3.0B, led by Celeres Capital founders.
Added in current filing · verify on EDGAR →
Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur immediate and substantial dilution upon the closing of this offering, assuming no value is ascribed to the warrants included in the units.
The company explicitly warns that public shareholders will experience immediate and substantial dilution because the sponsor acquired founder shares at a nominal price. This is a structural feature of SPACs and reduces the value of public shares from the outset.
Added in current filing · verify on EDGAR →
the Class A ordinary shares issuable in connection with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti-dilution rights of our founder shares intended to maintain the sponsor’s 20% ownership, which may result in an issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion.
The founder shares have anti-dilution rights designed to maintain the sponsor's 20% ownership, which could lead to issuance of additional Class A shares on a greater than one-to-one basis upon conversion. This further dilutes public shareholders beyond the initial founder share dilution.
Added in current filing · verify on EDGAR →
initially in the amount of $168,000,000, after payment of $7,000,000 of deferred underwriting fees (or $192,675,000 assuming no redemptions and after payment of $8,575,000 of deferred underwriting fees if the underwriters’ over-allotment option is exercised in full)
The company states the cash available for a business combination is $168 million after deferred underwriting fees, rising to $192.675 million if the over-allotment is fully exercised. These are preliminary figures from the S-1 and may change in the final pricing prospectus.
Added in current filing · verify on EDGAR →
The amount in the trust account is initially anticipated to be $10.00 per public share.
Public shareholders can redeem at approximately $10.00 per share, the initial trust value per public share. This is a preliminary estimate and the final per-share redemption amount will depend on the actual trust account balance.
Added in current filing · verify on EDGAR →
We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target.
The company has not identified or held substantive talks with any acquisition target, so investors cannot evaluate the merits or risks of the eventual business combination. This is standard for a SPAC at IPO but means the investment is essentially a bet on management's ability to find a deal.
Added in current filing · verify on EDGAR →
our sponsor, officers and directors have agreed to vote their founder shares, private placement shares and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions, aside from shares they may purchase in compliance with the requirements of Rule 14e-5 under the Exchange Act, which would not be voted in favor of approving the business combination transaction) in favor of our initial business combination
The sponsor, officers, and directors have contractually committed to vote all their shares in favor of any initial business combination. This increases the likelihood that a deal will be approved even if public shareholders oppose it, because the sponsor's founder shares and private placement shares are already aligned with management.
Added in current filing · verify on EDGAR →
prior to the closing of our initial business combination, only holders of our Class B ordinary shares (i) will have the right to vote to appoint and remove directors prior to or in connection with the completion of our initial business combination
Only Class B shareholders (the sponsor and insiders) can appoint or remove directors before a business combination closes. Public Class A shareholders have no say in board composition during the SPAC's search phase, concentrating control with the sponsor.
Added in current filing · verify on EDGAR →
the per-share redemption amount received by shareholders upon our dissolution would be approximately $10.00
If the SPAC fails to complete a business combination and liquidates, public shareholders are expected to receive about $10.00 per share from the trust account. However, the filing warns that creditor claims or other factors could reduce this amount below $10.00.
Experts · Experts
Withum Smith+Brown, PC audited Phalanx Acquisition Corp I's financial statements, with a going-concern explanatory paragraph.
Added in current filing · verify on EDGAR →
The financial statements of Phalanx Acquisition Corp I as of December 31, 2025 and for the period from August 28, 2025 (inception) through December 31, 2025 appearing in this prospectus have been audited by Withum Smith+Brown, PC, independent registered public accounting firm, as set forth in their report thereon (which includes an explanatory paragraph relating to Phalanx Acquisition Corp I’s ability to continue as a going concern), appearing elsewhere in this prospectus, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
The section identifies Withum Smith+Brown, PC as the independent auditor and discloses that their report includes a going-concern explanatory paragraph. This is a significant risk factor for investors, as it signals the auditor has substantial doubt about the company's ability to continue as a going concern.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify